Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Rhea-AI Summary

Citius Pharmaceuticals (CTXR) and its oncology subsidiary Citius Oncology (CTOR) announced their participation in the upcoming Jefferies Global Healthcare Conference in New York City from June 3-5, 2025. Chairman and CEO Leonard Mazur will deliver a presentation on Thursday, June 5, 2025, at 3:10 pm ET.

The presentation will be available via live webcast and archived for later viewing on the company's website. Additionally, Mr. Mazur will engage in one-on-one meetings with institutional investors during the conference. Interested investors can arrange meetings through their Jefferies representatives.

News Market Reaction – CTXR

+5.33%

1 alert

+5.33% News Effect

On the day this news was published, CTXR gained 5.33%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET

CRANFORD, N.J., May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City.

Conference Details:               

Presentation:	3:10 pm ET on Thursday, June 5, 2025*
Location:	New York City
Webcast:	A live and archived webcast of the presentation will be available here.    A replay will be available for a limited time following the presentation on the Events & Presentations portion of the Citius website www.citiuspharma.com.

 

In addition to the formal presentation, Mr. Mazur will participate in one-on-one meetings with institutional investors throughout the conference. Investors interested in scheduling a meeting should contact their Jefferies representative.

*Please note that the presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok^®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:

STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-302445210.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

When is Citius Pharmaceuticals (CTXR) presenting at the Jefferies Global Healthcare Conference 2025?

Citius Pharmaceuticals (CTXR) will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:10 pm ET in New York City.

Who will represent Citius Pharmaceuticals at the Jefferies Healthcare Conference 2025?

Leonard Mazur, Chairman and CEO of both Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR), will represent the companies at the conference.

How can investors watch CTXR's presentation at the Jefferies Conference?

Investors can watch the presentation via live webcast, which will be available on Citius Pharmaceuticals' website (www.citiuspharma.com) under the Events & Presentations section. A replay will be available for a limited time after the presentation.

Can investors meet with Citius Pharmaceuticals management at the Jefferies Conference?

Yes, CEO Leonard Mazur will be available for one-on-one meetings with institutional investors during the conference. Interested investors should contact their Jefferies representative to schedule a meeting.